Your session is about to expire
← Back to Search
Horizon Program for Graft-versus-Host Disease
Study Summary
This trial is testing whether a new, multidisciplinary approach to care can improve quality of life, symptoms, and psychological distress for people who have developed GVHD after a stem cell transplant.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are the hoped-for results of this experiment?
"This study will span a Baseline period to an 8 week follow up, with the primary evaluation criteria being adherence. Secondary objectives include assessing medical adherence via the Medication Adherence Report Scale (MARS-5), cancer self-efficacy through the Cancer Self-Efficacy Scale (CASE), and coping skills with Measure of Current Status (MOCS). Linear mixed models will be used to compare differences in these areas between groups, as indicated by their respective score range - MARS-5 5-25; CASE 0–170; MOCS 0–52 - where higher scores indicate greater success."
Is this research project presently recruiting participants?
"According to clinicaltrials.gov, this particular trial is not presently accepting participants. Originally posted on August 2nd 2020 and last updated on the 23rd of August 2022, there are currently 461 other medical studies in need of volunteers."
Share this study with friends
Copy Link
Messenger